917 related articles for article (PubMed ID: 28436755)
21. Novel vaccine development strategies for inducing mucosal immunity.
Fujkuyama Y; Tokuhara D; Kataoka K; Gilbert RS; McGhee JR; Yuki Y; Kiyono H; Fujihashi K
Expert Rev Vaccines; 2012 Mar; 11(3):367-79. PubMed ID: 22380827
[TBL] [Abstract][Full Text] [Related]
22. Strategies for mucosal vaccine development.
Boyaka PN; Marinaro M; Vancott JL; Takahashi I; Fujihashi K; Yamamoto M; van Ginkel FW; Jackson RJ; Kiyono H; McGhee JR
Am J Trop Med Hyg; 1999 Apr; 60(4 Suppl):35-45. PubMed ID: 10344675
[TBL] [Abstract][Full Text] [Related]
23. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
[TBL] [Abstract][Full Text] [Related]
24. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
25. Adjuvants for veterinary vaccines--types and modes of action.
Gerdts V
Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):456-63. PubMed ID: 26697712
[TBL] [Abstract][Full Text] [Related]
26. Optimizing efficacy of mucosal vaccines.
Gebril A; Alsaadi M; Acevedo R; Mullen AB; Ferro VA
Expert Rev Vaccines; 2012 Sep; 11(9):1139-55. PubMed ID: 23151169
[TBL] [Abstract][Full Text] [Related]
27. The role of adjuvants in the development of mucosal vaccines.
Vajdy M; Singh M
Expert Opin Biol Ther; 2005 Jul; 5(7):953-65. PubMed ID: 16018740
[TBL] [Abstract][Full Text] [Related]
28. Novel Adjuvants and Immunomodulators for Veterinary Vaccines.
Heegaard PM; Fang Y; Jungersen G
Methods Mol Biol; 2016; 1349():63-82. PubMed ID: 26458830
[TBL] [Abstract][Full Text] [Related]
29. Advances and challenges in mucosal adjuvant technology.
Newsted D; Fallahi F; Golshani A; Azizi A
Vaccine; 2015 May; 33(21):2399-405. PubMed ID: 25865473
[TBL] [Abstract][Full Text] [Related]
30. Recent developments in adjuvants for vaccines against infectious diseases.
O'Hagan DT; MacKichan ML; Singh M
Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
[TBL] [Abstract][Full Text] [Related]
31. Mucosal adjuvants: Opportunities and challenges.
Zeng L
Hum Vaccin Immunother; 2016 Sep; 12(9):2456-8. PubMed ID: 27159278
[TBL] [Abstract][Full Text] [Related]
32. Immunity in response to particulate antigen-delivery systems.
Storni T; Kündig TM; Senti G; Johansen P
Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
[TBL] [Abstract][Full Text] [Related]
33. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
Boyaka PN
J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
[TBL] [Abstract][Full Text] [Related]
34. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
Jin Z; Gao S; Cui X; Sun D; Zhao K
Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
[TBL] [Abstract][Full Text] [Related]
35. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
36. Vaccine adjuvants: putting innate immunity to work.
Coffman RL; Sher A; Seder RA
Immunity; 2010 Oct; 33(4):492-503. PubMed ID: 21029960
[TBL] [Abstract][Full Text] [Related]
37. B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.
Anjuère F; Bekri S; Bihl F; Braud VM; Cuburu N; Czerkinsky C; Hervouet C; Luci C
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():117-22. PubMed ID: 22882377
[TBL] [Abstract][Full Text] [Related]
38. Mucosal adjuvants.
Harandi AM; Medaglini D
Curr HIV Res; 2010 Jun; 8(4):330-5. PubMed ID: 20353395
[TBL] [Abstract][Full Text] [Related]
39. Rational application of nanoadjuvant for mucosal vaccine delivery system.
Dewangan HK
J Immunol Methods; 2020; 481-482():112791. PubMed ID: 32387695
[TBL] [Abstract][Full Text] [Related]
40. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.
Marciani DJ
Drug Discov Today; 2003 Oct; 8(20):934-43. PubMed ID: 14554157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
